Precision BioSciences

$1.61 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Precision BioSciences

Precision BioSciences, Inc. is a genome editing company. The Company is engaged in providing genome engineering technology. The Company’s ARCUS genome editing technology enables the production of specific nucleases that can insert, remove and modify deoxyribonucleic acid (DNA) at any location in a genome. The Company is also engaged in developing genome editing-based product leads for human therapeutic, agricultural and biologics manufacturing applications. The Company’s product candidates in its CAR T cell development pipeline are PBCAR0191, PBCAR20A, and PBCAR269A. The Company’s ARCUS platform designed to treat human diseases and create healthy and sustainable food and agricultural solutions. It also developing product candidates in three areas to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food.

Stock Analysis

last close $1.74
1-mo return 8.1%
3-mo return -9.8%
avg daily vol. 2.15M
52-week high 14.38
52-week low 1.11
market cap. $170M
forward pe -
annual div. -
roe -62.4%
ltg forecast -
dividend yield -
annual rev. $102M
inst own. 38.3%
baraka

Subscribe now for daily local and international financial news

Subscribe